Next Article in Journal
Preclinical Immunogenicity and Efficacy of a Multiple Antigen-Presenting System (MAPSTM) SARS-CoV-2 Vaccine
Next Article in Special Issue
Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens
Previous Article in Journal
Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies
Previous Article in Special Issue
Cellular Immunity—The Key to Long-Term Protection in Individuals Recovered from SARS-CoV-2 and after Vaccination
 
 
Review

Article Versions Notes

Vaccines 2022, 10(7), 1068; https://doi.org/10.3390/vaccines10071068
Action Date Notes Link
article pdf uploaded. 3 July 2022 08:56 CEST Version of Record https://www.mdpi.com/2076-393X/10/7/1068/pdf-vor
article xml file uploaded 6 July 2022 11:30 CEST Original file -
article xml uploaded. 6 July 2022 11:30 CEST Update https://www.mdpi.com/2076-393X/10/7/1068/xml
article pdf uploaded. 6 July 2022 11:30 CEST Updated version of record https://www.mdpi.com/2076-393X/10/7/1068/pdf
article html file updated 6 July 2022 11:31 CEST Original file -
article html file updated 12 August 2022 23:59 CEST Update https://www.mdpi.com/2076-393X/10/7/1068/html
Back to TopTop